Result: Risk Minimisation Materials for medicines starting with the letter O

Olumiant

Eli Lilly and Company Limited

Olumiant 2 mg and 4 mg Film-Coated Tablets guidance for Healthcare Professionals

Important Risk Minimization information for healthcare professionals prescribing Olumiant.

For Healthcare Professionals

Olumiant 2 mg and 4 mg Film-Coated Tablets Patient Alert Card

Olumiant 2 mg and 4 mg Film-Coated Tablets Patient Alert Card containing important safety information for patients.

OPDIVO

Bristol-Myers Squibb Pharmaceuticals limited

Opdivo (nivolumab) Important Safety Information To Minimise The Risks Of Immune-Related Adverse Reactions

This risk minimisation material is a condition of the marketing authorisation. This document is essential to ensure the safe and effective use of nivolumab or nivolumab in combination with ipilimumab, and appropriate management of immune-related adverse reactions which may include pneumonitis, colitis, hepatitis, nephritis and renal dysfunction, endocrinopathies, skin reactions and other immune-related adverse reactions, as well as potential complications of allogeneic Haematopoietic Stem Cell Transplant in classical Hodgkin Lymphoma. This educational material was UPDATED in Jan-2018. Changes to the material include an update to the “Other immune-related adverse reactions” section on page 6. In addition information on cases of Vogt-Koyanagi-Harada syndrome which has been reported post-marketing has also been included. If you would like a hard copy of the risk minimisation materials, please contact Bristol-Myers Squibb Medical Information (0800 731 1736; [email protected]).

For Healthcare Professionals

Opdivo (nivolumab) Patient Alert Card

This risk minimisation material is a condition of the marketing authorisation. Please ensure that you are familiar with this material as it contains important safety information that you need to be aware of before, during and after treatment with nivolumab or nivolumab in combination with ipilimumab. This educational material was UPDATED in Jan-2018. Changes to the material include editorial modifications to improve readability.

Oruvail

SANOFI

Oruvail Gel DHCP letter

DHCP letter, including Checklist for Prescribers and Information sheet for patients.

For Healthcare Professionals

Ozurdex

Allergan Ltd

Ozurdex - Patient Guide

A patient guide to OZURDEX therapy

Ozurdex - Physician injection guide

An Injector's Guide to OZURDEX

For Healthcare Professionals